Endurant Capital Management’s Alder Biopharmaceuticals ALDR Stock Holding History

Endurant Capital Management’s Portfolio ALDR Stock Details ALDR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-91,600	Closed	-$1.12M	–	103
2017 Q3	$1.12M	Buy	91,600 +49,300	+117%	+$514K	0.34%	64
2017 Q2	$484K	Buy	42,300 +5,600	+15%	+$104K	0.14%	86
2017 Q1	$763K	Buy	+36,700	New	+$812K	0.25%	72
2016 Q4	–	Sell	-19,500	Closed	-$639K	–	101
2016 Q3	$639K	Buy	19,500 +9,700	+99%	+$295K	0.24%	67
2016 Q2	$245K	Buy	+9,800	New	+$265K	0.08%	85

Other funds holding ALDR

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

FCMI

Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

PAMU

Pictet Asset Management (UK) London, United Kingdom $91.8B AUM 47.77% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

Endurant Capital Management's ALDR Position: Q4 2017 in Review

Endurant Capital Management sold out of Alder Biopharmaceuticals (ALDR) in Q4 2017, closing a stake of 91,600 shares — an estimated $1.12M sold.

Endurant Capital Management first reported a position in ALDR in Q2 2016 and held it in 5 quarters. The position peaked at $1.12M in Q3 2017. 140 funds tracked by Wall St. Rank hold ALDR as of Q4 2017.

Endurant Capital Management reported no remaining Alder Biopharmaceuticals position as of Q4 2017 after selling out during the quarter.
Endurant Capital Management sold 91,600 Alder Biopharmaceuticals shares in Q4 2017, an estimated $1.12M.
Endurant Capital Management first reported a position in Alder Biopharmaceuticals in Q2 2016 and held it in 5 quarters.
Endurant Capital Management's Alder Biopharmaceuticals position peaked at $1.12M in Q3 2017.
140 funds tracked by Wall St. Rank held Alder Biopharmaceuticals as of Q4 2017.

Based on Endurant Capital Management's 13F filing for Q4 2017, filed 14 Feb 2018.